Blueberry Therapeutics
Topical nanomedicines for treating dermatological conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 997.5x EV/Revenue -14.8x EV/EBITDA | round | |
£750k Valuation: £50.0m 997.5x EV/Revenue -14.8x EV/EBITDA | Late VC | ||
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (95 %) | 1092 % | 532 % | (100 %) | 11949 % | - | 20 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (24751 %) | (2970 %) | (684 %) | (1082627 %) | (6729 %) | (6748 %) | (6635 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (24967 %) | (2767 %) | (640 %) | (1045982 %) | (4076 %) | (5576 %) | (5492 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 70 % | - | - | - | - |
Source: Company filings or news article, Dealroom estimates
Related Content
Blueberry Therapeutics is a drug discovery and development company founded in 2011 by Michael John Davies and headquartered in Alderley Edge, United Kingdom. The company concentrates on creating topical nanomedicines for dermatological conditions, particularly infectious and inflammatory diseases of the skin and nail. Its primary business model involves using a proprietary nanopolymer drug delivery system, called Nanocin™, to enhance the delivery of existing drugs into the skin and nails. This approach aims to improve efficacy and safety, allowing for lower doses and shorter treatment durations compared to existing oral or topical treatments.
The company's lead product candidate, BB2603, is a topical nano-formulation of the antifungal drug terbinafine, delivered as a spray to treat onychomycosis (fungal nail infection) and tinea pedis (athlete's foot). In November 2023, Blueberry announced that its Phase 2b clinical trial for BB2603 met its primary and secondary endpoints, showing significant effectiveness after just three months of treatment. The company is also developing treatments for other conditions such as acne and atopic dermatitis.
Blueberry Therapeutics has raised a total of $23.8 million over five funding rounds since its first round in 2015. Key investors include China Medical System, Medical Incubator Japan, Maven Capital Partners, and the GM&C Life Sciences Fund. The funding has supported the clinical development of its product pipeline, with plans to advance BB2603 into Phase 3 trials in the US and EU. According to a filing in April 2024, the company was reported as out of business due to bankruptcy and liquidation.
Keywords: topical nanomedicines, drug delivery system, dermatology, onychomycosis, tinea pedis, fungal nail infection, terbinafine, athlete's foot, clinical trials, dermatological diseases, drug discovery, pharmaceutical, BB2603, Nanocin, skin infection, nail infection, anti-fungal, atopic dermatitis, acne treatment, biotechnology